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What you need to know 
1. Early symptoms of brain tumours in adults are non-specific and patients may present 
multiple times to primary care services before they are referred for investigation. Look 
out for symptoms of raised intracranial pressure (e.g. headaches exacerbated by lying 
down, triggered by Valsalva maneuver or associated with  vomiting or visual 
disturbance), combinations of symptoms (e.g. headache plus cognitive impairment, 
headache plus weakness, headache plus personality change) and symptoms which 
progress over time. New-onset focal or generalized seizures in adulthood also warrant 
investigation for a brain tumour. 
2. In patients with symptoms or signs suggestive of a brain tumour, arrange an urgent 
MRI head with and without contrast through a rapid-access ‘suspected cancer’ 
pathway, when available. In patients with suspicion of raised intracranial pressure, 
arrange a same-day clinical assessment and contrast-enhanced CT head scan.  
3. Glioblastoma (GBM) is the most common primary brain cancer. Standard treatment 
includes maximal safe resection followed by concomitant radiotherapy and 
temozolomide (TMZ) chemotherapy and then adjuvant TMZ. Disease progression is 
expected in all cases and consideration of further treatment should take into account 
the patient’s performance status, tumour size, location and time since first treatment 
4. Key supportive medications may include corticosteroids for vasogenic oedema and 
anti-epileptic medication if seizures occur 
5. Due to the incurable and rapidly progressive nature of glioblastoma, close 
collaboration between multidisciplinary teams in tertiary care hospitals and primary 
care services is recommended.  Early involvement of GPs and specialist community 
palliative care teams can assist patients and caregivers with advance care planning as 
well as management of symptoms, physical and cognitive impairment, communication 




Glioblastoma (GBM) is the most common primary brain cancer in adults (1). Despite surgical 
resection, chemotherapy and radiotherapy, median survival after diagnosis is only 14-16 
months (1–3). Disease progression is inevitable and results in worsening physical and cognitive 
disability, with early dependence on support from carers, general practitioners and palliative 
care services. Non-specialists play an important role from early referral of patients with 
suspected brain tumours, psychological support following diagnosis, management of 
medications and supportive care towards the end of life, and into bereavement for relatives. In 
this clinical update, we review the clinical presentation, investigation and management of 
patients with GBM.  
 
What is glioblastoma? 
GBM is a primary brain cancer which can arise anywhere within the central nervous system 
(CNS) but is most commonly located in the frontal or temporal lobes (4). Its origin within the 
CNS distinguishes it from the more common secondary brain cancers which occur due to  
metastasis from distant primary sites, most commonly lung, breast or skin (5). GBM belongs 
to a heterogeneous collection of brain tumours termed gliomas, which are thought to derive 
from glial cells or their precursors, and include astrocytomas and oligodendrogliomas (6). The 
former are classified by the World Health Organisation (WHO) as localised (grade I) or diffuse 
(grades II-IV), with increasing grade reflecting more aggressive tumour phenotypes (7). GBM 
is a grade IV diffuse astrocytoma, a highly malignant subtype with high rates of cell division, 
vascular proliferation and central areas of tumour necrosis (7,8).  
 
How common is it? 
GBM has an annual incidence of 3-5 per 100, 000 people (3,9,10). While the disease can occur 
in children and adults, median age at diagnosis is 65 years (9). It is approximately 1.6 times 
more common in males than females, the reason for which remains uncertain (3,9). 
 
What are the risk factors? 
The vast majority of patients with GBM do not have any identifiable risk factors for tumour 
development (11). Some rare familial cancer syndromes including neurofibromatosis type 1, 
tuberous sclerosis, Lynch syndrome and Li-Fraumeni syndrome are associated with an 
increased risk of GBM (12). Suspicion of an inherited cancer syndrome should prompt referral 
to a clinical geneticist to guide further investigation and follow-up. The only established non-
genetic risk is a history of exposure to ionising radiation (13). Atopic conditions  have been 
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identified as a protective factor, reducing the risk of glioma by approximately 30% (13). 
Epidemiological evidence does not support an association between use of cellular telephones 
and risk of brain tumour development (13). 
 
How do patients present in primary care? 
The initial presentation of patients with GBM is frequently non-specific, with broadly similar 
signs and symptoms seen with other primary or secondary brain tumours, as well as more 
common benign neurological conditions. Approximately half of patients are diagnosed 
following an emergency hospital presentation (14). Most will have attended their GP with 
symptoms prior to diagnosis, often on multiple occasions (15,16). Despite this, only 2% of 
patients in England are currently diagnosed via the ’suspected cancer’ pathway which provides 
GPs with direct access to magnetic resonance imaging (MRI) brain scans within two weeks 
(14,16). This reflects the significant challenge of identifying suspected cases of brain tumours 
in primary care, where early symptoms often overlap with common benign conditions. In the 
UK, introduction of a national awareness campaign to improve recognition of early symptoms 
of brain tumours in children (HeadSmart) has reduced the time interval from onset of symptoms 
to diagnosis (17). An equivalent strategy for adult patients is yet to be developed.  
 
Headache is the most common early symptom of brain tumours [Figure 1], but as few as 1-2 
in 1000 patients who consult their GP with this symptom are later diagnosed with a brain 
tumour (18–20). Headache characteristics vary based on tumour location, size and rate of 
growth (21,22) and can be ‘tension-type’ or migrainous in nature. They tend to be exacerbated 
by supine position and are therefore most noticeable on waking. Headaches can also be 
precipitated by coughing or Valsalva manoeuvre. They tend to increase in frequency or severity 
over time. The development of additional neurological symptoms or signs in combination with 
headaches significantly increase the likelihood of an underlying brain tumour [Figure 1]. For 
example, new headache reported alongside weakness or cognitive dysfunction increase the 
likelihood of a brain tumour by 44 and 59-fold, respectively (18).  
 
Seizures are a presenting symptom in approximately 20% of patients with GBM and an 
additional 20% develop seizures later in the disease (11,23). While a less common presentation 
in the primary care setting, new onset seizure in adulthood has the greatest positive predictive 
value (PPV) of all individual symptoms (1.6%), followed by motor weakness (1.5%) and 
confusion (1.4%) (18). Various other presenting symptoms have been linked to brain tumours 
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[Figure 1], however each has a PPV of less than 1% (18). Combinations of symptoms, 
especially if progressive in nature, significantly increase the likelihood of an intracranial 
tumour being identified on MRI scan (24,25).  
 
What to cover on initial assessment? 
History: Establish the nature and temporal progression of the presenting symptoms. A 
collateral history from family members, friends or work colleagues can be very informative 
since patients are often unaware of subtle changes in personality or behaviour over time (26). 
A recent qualitative study of patient experiences of brain tumour diagnosis found that most 
patients and family members had noticed multiple mild symptoms or ‘changes’ (e.g. “My head 
felt fuzzy”, “You weren’t quite yourself”) at least 6 months before their initial presentation 
(16). It is therefore important to review recent consultation records and empower patients who 
are not referred to keep a symptom diary and return if they feel something is still wrong (16,18). 
 
For patients presenting with headache, inquire about high-risk clinical features which raise 
suspicion of a possible brain tumour [Box 1]. Also ask if there is any history of systemic 
malignancy, previous radiation exposure or family history of inheritable cancer syndromes 
which independently increase the likelihood of a brain tumour diagnosis (27,28). Focal 
neurological deficits associated with brain tumours usually develop gradually over the course 
of weeks to months; acute deficits are more likely related to cerebrovascular ischaemia or 
haemorrhage in the tumour. If a possible seizure is reported, inquire about preceding aura, a 
description of the event, as well as the presence of any tongue-biting, incontinence, post-ictal 
confusion or fatigue. Temporal lobe seizures are often missed since they present as an abrupt 
change in a patient’s behaviour rather than tonic-clonic limb movements. They may be 
preceded by the sensation of an abnormal smell/taste or feeling of gastric uprising. When a 
history of seizure is suspected, patients should be given advice to avoid potentially dangerous 
work or leisure activities and told to stop driving while awaiting confirmation of diagnosis by 
a specialist. Family or caregivers, should be offered first aid advice on how to recognise and 
manage further seizures if they occur.   
 
Examination: Perform a neurological examination of the cranial nerves, motor, sensory and 
cerebellar systems. In patients with symptoms suggestive of elevated intracranial pressure 
(ICP), examine the optic discs for signs of papilloedema or refer to local optician services for 
digital retinal photography. Routine use of cognitive screening tests such as the Mini Mental 
6 
State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) is not recommended 
since they lack sensitivity to detect subtle, domain-specific neurocognitive deficits in patients 
with GBM (29,30). 
 
What differential diagnosis to consider? 
Differential diagnosis will vary based on the duration, chronological sequence and anatomical 
localisation of symptoms and signs. Due to the non-specific nature of most brain tumour 
presentations, a range of different neurological conditions should be considered as alternative 
diagnoses or co-existent disorders. In patients with an established  diagnosis of a primary 
headache disorder (e.g. tension-type headaches, migraines), a symptom diary can help to 
establish whether there has been a sufficient change in the frequency or characteristic of 
headache symptoms to warrant further investigation.  
 
How to investigate? 
If patients present with symptoms or signs of raised ICP (e.g. headache with papilloedema), 
refer them to the emergency department for same-day assessment and initial investigation with 
a contrast-enhanced CT head scan. If there is a history of possible new-onset seizure, arrange 
urgent referral to a specialist with expertise in epilepsy (e.g. a ‘first fit’ clinic) for confirmation 
of diagnosis and further investigations (e.g. contrast-enhanced MRI head, 
electroencephalogram) (31). For patients with a suspected brain tumour who do not display 
features suggestive of raised ICP or possible seizure activity, request an urgent MRI brain scan 
(including pre- and post-gadolinium contrast T1-weighted, T2-weighted, FLAIR and DWI 
sequences) (28,32), using a rapid-access ‘suspected cancer’ pathway, where available. In 
resource-limited settings, or in patients with contra-indications to MRI (e.g. non-MRI 
conditional devices, severe claustrophobia), a contrast-enhanced CT head scan is a less 
sensitive, but still valuable, alternative initial investigation.  
 
The route of access to urgent neuroimaging varies by geographical region. In England, the 
National Institute for Health & Care Excellence (NICE) advise GPs to refer patients greater 
than 24 years of age with a ‘progressive, sub-acute loss of central neurological function’ for an 
urgent direct access MRI brain scan within 2 weeks (33). In contrast, NHS Scotland 
recommend an urgent referral to a specialist (e.g. neuro-oncologist) who subsequently arranges 
neuroimaging, if required (34). At time of referral, inform patients that they are being referred 
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in case they have cancer but also provide reassurance that the majority are not subsequently 
diagnosed with cancer (33).  
 
Patients presenting with a suspected primary headache disorder and no high-risk features may 
still request a scan for reassurance that there is no serious underlying cause of their symptoms 
(35). This presents a significant dilemma for GPs who must balance the need to limit 
unnecessary investigations with their own concern about missing a brain tumour. Beside 
resource limitations, there are potential risks associated with neuroimaging which need to be 
considered (e.g. radiation exposure from CT scan, anaphylaxis from contrast agents) (36). 
Approximately 1 in every 37 MRI brain scans will also yield an incidental abnormality (37) 
which could require further specialist management or follow-up (e.g. aneurysm, arachnoid 
cyst, meningioma). While a reassuring scan can reduce service use for headaches in patients 
with high levels of psychological morbidity, it does not lead to lasting improvement in 
headache or anxiety symptoms (36). There is also a lack of evidence to suggest that earlier 
neuroimaging of patients with GBM who initially present with headaches would translate to 
any difference in clinical outcome. Patients without an indication for urgent neuroimaging 
should therefore be offered reassurance and encouraged to return if symptoms worsen or 
additional clinical features develop.  
  
The classic MRI appearance of GBM is a mass lesion with peripheral contrast-enhancement 
on T1-weighted imaging (blood-brain barrier disruption), central hypointesity on T2-weighted 
images (necrosis) and surrounding hyper-intensity on T2-weighted and fluid-attenuated 
inversion recovery (FLAIR) images representing vasogenic oedema or infiltrating tumour 
[Figure 2] (38). Additional sequences such as diffusion-weighted imaging (DWI) can help to 
discriminate GBM from other contrast-enhancing mass lesions such as cerebral abscess or CNS 
lymphoma (38). Perfusion MRI and amino acid positron emission tomography (PET) scan 
imaging may be used to identify metabolic hotspots suitable for tissue sampling in patients 
undergoing biopsy as opposed to surgical resection (28). 
 
How is it treated? 
If imaging reveals a suspected brain tumour, refer the patient to a specialist neuro-oncology 
multi-disciplinary team (MDT) for confirmation of the diagnosis and further management 
[Figure 3] (32). For suspected GBM, first-line management is to offer maximal surgical 
resection for local tumour control prior to adjuvant treatment (28). In addition to obtaining 
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tissue for histopathological diagnosis, surgery aims to improve neurological function, facilitate 
steroid weaning, prolong survival and improve quality of life (28,39). In patients who are 
elderly, have a poor performance status or a tumour not amenable to surgical resection, the 
MDT may offer a less invasive biopsy procedure (28,32). If  biopsy risk is considered too high 
or prognosis is likely to be very unfavourable, best supportive care alone or a short course of 
palliative radiotherapy is considered  (28).  
    
A recent systematic review and meta-analysis showed that greater extent of resection improved 
survival in patients with GBM (40). On the contrary, intra-operative injury to ‘eloquent’ brain 
tissue that is responsible for control of movement, sensation or speech, is associated with 
reduced quality of life and overall survival (41). To help maximise the extent of resection while 
minimising risk of post-operative disability various surgical adjuncts have been developed, 
including intra-operative neuroanatomical navigation systems, ultrasound, fluorescent dyes to 
visualise tumour tissue and cortical mapping in awake patients (28). Tumour specimens are 
classified and graded according to the WHO classification for CNS tumours, which was 
updated in 2016 to incorporate various molecular markers in addition to microscopic 
appearances (7,42). For GBM, an important genetic distinction is between tumours with and 
without mutations in genes encoding the metabolic enzyme isocitrate dehydrogenase (IDH). 
Despite similar histological appearances, IDH wild-type GBM has a more aggressive 
phenotype with a median survival of 15 months compared with 31 months in patients with an 
IDH-mutated GBM (43).  
 
Following resection or biopsy, the additional treatment which is offered depends on age and 
performance status [Figure 3] (28,32). The standard treatment protocol for patients aged under 
70 years who are capable of independent self-care (i.e. Karnofsky performance status ≥ 
70) is daily fractionated radiation therapy over 6 weeks with concurrent and adjuvant 
temozolomide, an oral alkylating chemotherapy, for a maximum of 6 months (2,28,32). Older 
patients with a similar performance status can be offered an abbreviated course of 
hypofractionated radiotherapy with concurrent and adjuvant temozolomide for up to 12 months 
(28,32,44). In patients with IDH wild-type glioblastoma, response to temozolomide 
chemotherapy can be predicted by the promoter methylation status of the O6-methylguanine 
DNA methyltransferase (MGMT) gene which encodes a DNA repair enzyme known to 
antagonise the effect of alkylating chemotherapy (42). Epigenetic silencing in MGMT 
promoter-methylated tumours therefore confers heightened response to temozolomide and 
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improved survival, with only marginal effects in MGMT promoter-unmethylated tumours 
(28,42).    
 
What is the prognosis? 
In adults aged under 70 years who do not undergo surgery, median survival is approximately 
3-4.5 months (3,45). A biopsy procedure followed by chemotherapy, with or without 
radiotherapy, improves median survival to 8-10 months (2,3,45). Maximal treatment with 
debulking surgery followed by chemoradiotherapy is associated with the longest median 
survival of around 15-16 months (2,3,45).  
 
Elderly patients who receive best supportive care alone are expected to have a median survival 
of less than 4 months (1). In patients aged over 65 years who have undergone biopsy or 
resection, hypofractionated radiotherapy and chemotherapy improve median survival from 7 
to 9 months, compared with radiation alone (44). Despite evidence of a survival advantage, 
addition of adjuvant chemotherapy does not improve quality of life in this group (44). Due to 
the incurable nature of GBM, patients should be appropriately counselled about the potential 
impact of adverse effects of treatments on quality of life and not only potential survival 
benefits, especially in elderly patients and those with a poor performance status who have a 
particularly poor prognosis. 
 
What supportive medication may be required? 
Corticosteroids: The vast majority of patients with GBM receive corticosteroids during the 
course of their disease. This can relieve headache, nausea and vomiting by reducing 
peritumoral vasogenic oedema and mass effect (23). Dexamethasone is the preferred choice 
and can be commenced prior to surgery unless there is a suspicion of primary cerebral 
lymphoma or an inflammatory CNS lesion as steroids can confound diagnosis in this setting 
(28). There is no consensus on optimal dosing and steroid requirements vary according to 
tumour size, location, peritumoral oedema and symptoms. Since patients with GBM can often 
remain on steroids for several months, they are at increased risk of the long-term side effects 
of steroids [Table 1]. Steroid-induced hyperglycaemia is a common adverse effect which can 
not only exacerbate hyperglycaemia in patients with known diabetes mellitus (DM), but also 
may lead to the onset of DM in patients without a prior history of the condition (46). The aim 
should be to use steroids for a short period of time and, if patients remain symptomatic, to taper 
to the lowest possible maintenance dose that controls symptoms. Gastric protection with 
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proton-pump inhibitor or H2-receptor antagonist is recommended for patients taking regular 
corticosteroids.  
 
Anti-epileptic drugs (AEDs): AEDs are recommended for patients who have had a seizure, but 
there is no good-quality evidence to support their prophylactic use (11,28,47,48). National 
clinical guidelines recommend choice of formulation based on various factors, including age 
and seizure type (31,51). Non-enzyme inducing AEDs are preferred to avoid interactions with 
chemotherapy and steroids (48). Some AEDs may lack efficacy in patients with GBM due to 
loss or receptor sensitivity or expression of multidrug-resistance proteins, which can result in 
refractory epilepsy (49,50). Levetiracetam is often the first drug of choice in most neuro-
oncology centres [Table 1] since it is usually well-tolerated, can be initiated orally at a 
therapeutic dose, does not require monitoring and is not thought to be affected multi-drug 
resistance proteins (23,48–50). There is no consensus regarding the optimal duration of AED 
therapy in GBM patients and many clinicians therefore opt to continue AEDs indefinitely if 
they are well tolerated (51). Any decision to discontinue AEDs should take into account seizure 
history, tumour residual, anticipated tumour growth, medication side effects and patient 
preference (51).    
 
Venous thromboembolism (VTE): Patients with GBM are at increased risk of VTE in the peri-
operative period and beyond, with a 1 year incidence of around 20% (52). A large randomised, 
double-blind study in post-operative elective neurosurgery inpatients, most of whom had brain 
tumours, showed that prophylactic low molecular weight heparin (LMWH) was effective in 
reducing the rate of VTE without increasing the risk of haemorrhagic complications (53). There 
is, however, no good-quality evidence to support the use of continuing prophylactic LMWH 
on discharge (11,23). If patients with GBM develop VTE, therapeutic anticoagulation is 
generally considered safe, unless there has been recent haemorrhage from the tumour or 
chemotherapy-related thrombocytopenia (11,54). There is currently no consensus on the 
preferred choice of anticoagulant or duration of treatment in this patient group.      
 
Cognitive and mood disturbances: Approximately 9 in 10 patients with brain tumours display 
cognitive deficits before commencing treatment (55). This is likely to be exacerbated by 
cancer-related fatigue and sleep disturbance (11). Randomised controlled trials (RCTs) to date 
have failed to show a beneficial effect of acetylcholinesterase inhibitors or psychostimulants 
in overall rates of cognitive decline or symptoms of fatigue in this group (11,54). Depression 
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can affect 1 in 5 patients with glioma (56). No RCTs to date have investigated the efficacy of 
pharmacological treatments for depression in this patient group (57).  
 
What advice should be given on driving? 
Inform patients with a new diagnosis of GBM that they must not drive and must notify the 
driver licensing authority of their condition. Following treatment, the judgement on whether a 
patient has the competency to start driving again is not only based on history of epileptic 
seizure, but also the presence of any neurological or cognitive deficits (48).   
 
How are patients followed-up? 
Follow-up is usually co-ordinated by a neuro-oncologist and is an opportunity to monitor the 
physical and psychological wellbeing of patients and caregivers. For patients receiving 
adjuvant temozolomide, a full blood count is performed weekly due to risk of 
myelosuppression, with addition of monthly renal and liver function tests. If the tumour is 
located close to the hypothalamus or pituitary, endocrine tests to monitor hypothalamic-
pituitary axis function are recommended (58). Repeat neuroimaging is critical in establishing 
response to treatment and monitoring for disease recurrence. A baseline gadolinium-enhanced 
MRI brain scan is performed 24-48 hours following surgery(28). This is usually compared with 
a repeat MRI scan 1-2 months after completion of radiotherapy to determine initial response to 
treatment. The subsequent schedule for clinical reviews and follow-up imaging is usually at 3 
monthly intervals or sooner dependent upon the volume of residual tumour, response to 
treatment, patient preference and life expectancy (32).  
 
If a patient develops worsening headaches or a new focal neurological deficit before their next 
review, arrange an urgent clinical assessment to determine if a repeat MRI (or CT) scan is 
required (32).  
 
How is disease recurrence managed? 
In spite of surgical resection and chemoradiotherapy, GBM invariably recurs (59). Up to 80% 
of tumour recurrences are within 2 cm of the initial tumor site; the remainder arise in distant 
brain regions, suggesting microscopic invasion of tumour cells beyond the original resection 
margin (59,60). Recurrent GBM is frequently more aggressive and less treatment-responsive 
than the initial tumour (59). Further treatment options are at the discretion of the specialist 
neuro-oncology MDT who take into account tumour phenotype, time since last treatment, 
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patient preference and performance status (32). If there is focal recurrence of disease, repeat 
surgical resection is an option (32). Further radiotherapy can also be considered depending on 
the time since original treatment and location of disease (32). Early randomised trial results 
suggest this approach could prolong progression-free survival without an overall survival 
benefit (61).   If further chemotherapy is considered, options include lomustine,  or combination 
therapy with procarbazine, lomustine and vincristine (PCV) (32). Inclusion into a clinical trial 
can also be considered (28). If a patient does not wish to receive further treatment, or additional 
disease-modifying therapy is unlikely to be of clinical benefit, an active  palliative care 
approach is favoured (32).  
 
What is the typical illness experience of patients with GBM and their carers? 
Patients with GBM have been found to have archetypical trajectories of physical, social, 
psychological and existential distress which start even before a diagnosis is confirmed (62). 
Social decline may follow a similar pattern to that of physical decline, whereas psychological 
and existential distress are typically acute at 4 stages: around diagnosis, after initial treatment, 
at disease progression and at the end of life.  We define existential or spiritual issues as relating 
to the meaning and purpose of life (63).  Each patient’s individual course varies according to 
other factors including co-morbidities and the availability of individual  family and community 
resources (e.g., personal resilience and emotional support). As previously  described with 
progressive lung cancer (64),  patients and family carers of patients with GBM may follow a 
roller-coaster experience as they experience worry and distress [Figure 4]. 
 
Understanding these typical illness experiences allows health and social care professionals to 
predict their patients’ and carers’ likely needs so they can provide appropriate support and 
sensitive and effective communication from before diagnosis to bereavement support to the 
carer. [Box 3]. Early provision of a palliative care approach by GPs and hospital clinicians, not 
just by palliative care specialists, can have a significant impact in improving the quality of life 











BOX 1: High-risk features of headaches associated with brain tumours*      
▪ Headache triggered by cough, valsalva, sneeze or exercise 
▪ Orthostatic headache (exacerbated by supine position) 
▪ A substantial change in headache characteristics  
▪ Associated with new-onset neurological deficit, change in personality or cognitive 
dysfunction 
▪ Impaired level of consciousness 
▪ Vomiting without other obvious cause 
▪ History of malignancy known to metastasise to brain 
 




























BOX 2: The carer’s perspective 
 
Our lives were shattered when he suddenly experienced a terrifying grand mal seizure. He was 
rushed to A&E and kept in for numerous tests. The consultant informed him in a very matter-
of-fact manner that he had a brain tumour. It was before visiting hours, so he was on his own 
when he was given this devastating news. Looking back, he had always had headaches for as 
long as I had known him. Before the seizure, he had been quite tired and was having afternoon 
naps. He had also vomited once, but we thought it might be an upset stomach.  
 
He was referred a neurosurgeon and underwent a resection craniotomy. Unfortunately, a few 
days later we received the crushing news that it was a glioblastoma with a prognosis of less 
than 15 months. One of the biggest blows, was being told that he could not drive again. Losing 
his licence meant losing his independence. He started 6 weeks of daily radiotherapy, followed 
by 12 months of chemotherapy. He realized early on that by simply following the standard 
treatment plan, he was not going to live life to the full. Learning about diet, exercise, wellbeing, 
relationships, resilience and managing stress had a huge impact on his state of mind. When he 
became bed-bound, community nurses would visit our home to wash and dress him. I do not 
know what I would have done without them. Staff at the hospice were so kind and 
compassionate, and allowed me to stay every day and night. It was the first time since his 
diagnosis that I felt I could be his wife, and not just his carer. 
 
If I were to share our experience with doctors, I would say please always be empathic. For 
example, when he first started taking dexamethasone and stopped sleeping at night and became 
agitated, I thought he had changed forever. It would have been helpful to know that these 
changes might happen and that they would be temporary.  
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The most important thing for a patient is to feel that they have some sort of control of their 










• acknowledge that uncertainty while awaiting diagnosis can be distressing 
Around diagnosis: 
• offer further information about the diagnosis and what will likely happen next 
• signpost to relevant organisations such as brain cancer charities that offer support 
During initial treatment: 
• listen to and explore any problems or questions that the patient may have 
• offer supportive advice to caregivers and allow them to ask questions 
• facilitate prompt communication between primary care and hospital teams 
At follow-up visits with specialist or general practitioner: 
• identify a named contact (e.g. specialist nurse or family physician) who can offer 
psycho-social support and practical advice  
• discuss what the future may hold, and together document a care plan and send a 
summary electronically to all settings including urgent and emergency care 
• engage caregivers in discussions about what practical assistance may be helpful 
Disease progression 
• offer patients the opportunity to review their future care plan, including sensitive 
discussion of their resuscitation preferences, and preferred place of death 
• seek patient consent to involve caregivers in discussions about end-of-life care  
• regularly communicate the revised care plan with all involved, including out-of-hours 
services 
• stay in contact and establish if additional support is required 
Bereavement 
• offer an initial bereavement visit from a known healthcare professional 





Other article boxes 
 
Source & selection criteria 
We searched PubMed using the terms “Glioblastoma”, “Glioma” or “Astrocytoma”. We also 
hand-searched reference lists of included papers. In addition, for clinical guidelines we 
searched the websites of the National Institute for Health & Care Excellence (NICE), the 
European Association of Neuro-Oncology (EANO) and BMJ Best Practice. We reference and 
draw conclusions from large cohort studies, randomised clinical trials and systematic reviews 
with or without meta-analysis.  
 
Information resources for patients 
 Macmillan Cancer Support (https://www.macmillan.org.uk/) - Offers support to patients 
diagnosed with any cancer in the UK 
 Brainstrust charity (https://brainstrust.org.uk) - Offers specialist support to patients 
diagnosed with brain tumours in the UK 
 Marie Curie charity (https://www.mariecurie.org.uk) - Offers care and support to patients 
with terminal illnesses and their families. Provides advice on advance care planning.  
 
Education into practice 
 What symptoms and signs would make you consider a possible diagnosis of a brain 
tumour? 
 How are patients with suspected brain tumours initially investigated? 
 What is the current standard treatment of glioblastoma in adult patients? 
 Think about the last time you reviewed a patient with brain cancer. Did you inquire 
about caregiver wellbeing and establish if they require additional support? 
 
Questions for future research 
 Are there any biomarkers which could expedite GBM diagnosis and monitor treatment 
response? 
 What interventions can shorten the time to diagnosis and do these affect survival 
outcome? 
 How can clinical trial design be adapted to examine the efficacy of future targeted drug 
therapies? 
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How patients were involved in the creation of this article 
We invited a caregiver to write a personal account of their partner’s glioblastoma diagnosis and 
treatment, as well as to comment on what they felt doctors reading this article should know 
[Box 2]. In addition, we invited a representative of the brain tumour community to comment 
on the manuscript. They added some practical suggestions for clinicians caring for patients 
with glioma and their caregivers [Box 3], as well as making textual edits to the manuscript. We 
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Fig 1: Frequency of symptoms reported to general practitioners in 6 months prior to 
brain tumour diagnosis. Adapted from Ozawa M et al, 2019. (18) 
 
Fig 2: Axial MRI head scan with (A) gadolinium-enhanced T1-weighted, (B) T2-weighted 
and (C) FLAIR sequences demonstrating a right parietal glioblastoma. 
 
Fig 3: Glioblastoma management pathway.  Adapted from NICE guideline NG99 (2018) 
(32). †Consider biopsy if surgical resection not considered possible (e.g. poor performance 
status). ††Consider if histopathological diagnosis cannot be made due to high risk of biopsy or 
very unfavourable prognosis (28).  
 
Fig 4: Typical fluctuations in trajectories of physical, social, psychological and spiritual 
wellbeing in patients with GBM and their family carers. Adapted from Murray et al., 2010 
(64).  
 
 
